FusionPlex® Dx is an RNA-based targeted gene panel for detecting gene fusions and oncogenic isoforms implicated in the most prevalent solid tumors, especially non-small cell lung cancer (NSCLC). The panel covers ESMO-recommended targets including MET, NTRK1-3, ALK, ROS1, and RET, in addition to pan-tumor comprehensive genomic profiling, and provides highly actionable and quick therapy guidance. Coverage also includes 41 analytical targets, such as FGFR1-3 and NRG1, plus additional key targets to advance precision oncology by providing broader therapy options and optimal clinical trial enrollment. The panel is validated for use on Illumina® MiSeqDx and Illumina NextSeq 550Dx sequencers. It is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect gene fusions and oncogenic isoforms in a single sequencing product, even without prior knowledge of gene fusion partners or breakpoints.
Content meets ESMO and country-specific guidelines
Superior Fusion Detection for Better Therapy Selection
AMP RNA-based assays detect both known and novel fusions and can help you identify more patients who may be eligible for fusion-directed therapies.
Scalable and Flexible
Adaptable to flexible laboratory throughput and validated on MiseqDx and NextSeq 550Dx instruments.
Quick and Simple Workflow
Easy-to-handle lyophilized reagents and a simple workflow minimize errors and reduce turnaround time for better routine testing.
Number of Reads per Library
MiSeqDx: 1-3 M, NextSeq 550 Dx: 1-3 M
Library prep ~3.5 hrs; sequencing ~1 hr
Results on day 5, starting w/ extracted nucleic acid
MiSeqDx or NextSeq 550Dx
* Included in international and or local guidelines for NSCLC